24 February 2021 - PHARMAC knew there were clinical reasons some epilepsy patients would not tolerate a change to their medicines. 

But the drug buying agency went ahead with a switch that forced more than 10,000 people to change brands of the anti-epileptic drug lamotrigine anyway.

That admission was contained in evidence presented by PHARMAC today at the Chief Coroner's Inquest into whether the brand switch had any role in the deaths of six people, who died after changing epilepsy medication.

Read Radio New Zealand article